Formerly known as Apeliotus Technologies Inc, Maculogix Inc is a pharmaceutical company developing tools for early detection. tracking and diagnosis of retinal diseases, particularly age-related macular degeneration (AMD), a cause of blindness. The Companyâs AdaptDx® is the first practical measurement tool for dark adaptation - the transition from being light-adapted to being dark-adapted.- and known to be substantially impaired in degenerative diseases of the macula such as age-related macular degeneration (AMD) and inherited macular dystrophies. MacuLogixâ AdaptDx⢠has received FDA 510(k) clearance for measurement of dark adaptation function and patient testing has been completed to support validation as a diagnostic for AMD. In use by a number of pharmaceutical companies, AdaptDx⢠is not currently cleared for sale as a diagnostic. AdaptDx⢠is also involved in the development of drugs for early AMD. Based on significant technical advances, the AdaptDx provides doctors with an easy-to-use functional test similar to routine perimetry testing for glaucoma. AdaptDX is designed to function as a screening tool to enable doctors to identify individuals at the earliest stages of AMD and track the disease for treatment and is being used by a number of pharmaceutical companies in the development of drugs for early AMD The firm's AdaptDx⢠has received FDA 510(k) clearance for measurement of dark adaptation function and patient testing has been completed to support validation as a diagnostic for AMD. However, to date (April 2017) the AdaptDx⢠is not currently cleared for sale as
